JNJ-pan-AR
JNJ-pan-AR is an orally active androgen receptor (AR) inhibitor with an IC50 of 19 nM and a Ki of 8.4 nM against human wild-type AR. JNJ-pan-AR abolishes androgen-induced KLK2 and KLK3 mRNA expression and reduces androgen-dependent colony formation in prostate cancer cells. JNJ-pan-AR blocks AR nuclear translocation, inhibits PSA protein expression, and represses the growth of AR-dependent tumor cells and ARF877L-driven tumor xenografts. JNJ-pan-AR blocks transactivation and signaling of wild-type AR and various mutant AR variants. JNJ-pan-AR is applicable for research on castration-resistant prostate cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1332390-06-3
- Formel: C25H24F3N5O2S
- Molecular Weight:515.55
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| VCaP | IC50 |
92 nM
Compound: 4; JNJ-pan-AR
|
Antiproliferative activity against human VCaP cells expressing wild-type androgen receptor assessed as reduction in cell viability incubated for 5 days in presence of R1881 by CellTiter-glo assay
Antiproliferative activity against human VCaP cells expressing wild-type androgen receptor assessed as reduction in cell viability incubated for 5 days in presence of R1881 by CellTiter-glo assay
|
[PMID: 33470111] |
| VCaP | IC50 |
92 nM
Compound: 4; JNJ-pan-AR
|
Antiproliferative activity against human VCaP cells expressing wild type AR assessed as reduction in R1881-stimulated cell proliferation measured after 5 days by Celltiter-Glo luminescence assay
Antiproliferative activity against human VCaP cells expressing wild type AR assessed as reduction in R1881-stimulated cell proliferation measured after 5 days by Celltiter-Glo luminescence assay
|
[PMID: 34422225] |
In Vitro
JNJ-pan-AR (compound 4) potently and selectively binds to wild-type androgen receptor with an IC50 of 19 nM and a Ki of 8.4 nM, and has minimal affinity for glucocorticoid receptor[1].
JNJ-pan-AR acted as a complete antagonist in HepG2, LNCaP, and VCaP cells expressing wild-type and mutant androgen receptors such as F877L, L702H, T878A, W742C, and W875L, with no agonistic activity. Its IC50 values against HepG2 cells, LNCaP F877 cells, LNCaP AR cs cells, and wild-type AR VCaP cells transiently transfected with VP16-AR F877L were 127 nM, 98 nM, 191 nM, and 92 nM, respectively. It also effectively antagonized the transcriptional activity of various androgen receptor ligand-binding domain mutants in HepG2 cells[1].
JNJ-pan-AR potently blocks nuclear translocation of ARF877L mutant androgen receptor and inhibits PSA expression in LNCaP F877L cells, regardless of androgen stimulation[1].
JNJ-pan-AR inhibits androgen-stimulated nuclear translocation of wild-type androgen receptor in LNCaP cells[1].
JNJ-pan-AR (0.01-10 μM; 24 h) potently inhibits androgen-mediated KLK2 and KLK3 mRNA expression in LNCaP prostate cancer cells[2].
JNJ-pan-AR (0.062-1 μM; 14 day) inhibits androgen-driven colony formation in LNCaP prostate cancer cells[2].
JNJ-pan-AR (10 μM; >3 months chronic exposure, continuous maintenance) generates LNCaP JNJR prostate cancer cells with acquired resistance to JNJ-pan-AR, characterized by altered morphology and reduced growth rate[2].
JNJ-pan-AR (0.1-10 μM; 14 day) shows that exogenous AKR1C3 expression induces partial resistance to JNJ-pan-AR in LNCaP prostate cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LNCaP (AR-mutant T877A) prostate cancer cells
-
Concentration:0.01 μM, 0.1 μM, 1 μM, 10 μM
-
Incubation Time:24 h
-
Result:Suppressed androgen-mediated induction of KLK2 and KLK3 mRNA expression in a concentration-dependent manner.
Reduced KLK2 mRNA fold change to ~15 (from ~50 with DMSO + R1881) at 10 μM.
Reduced KLK3 mRNA fold change to ~6 (from ~14 with DMSO + R1881) at 10 μM.
-
Cell Line:LNCaP (AR-mutant T877A) prostate cancer cells
-
Concentration:0.062 μM, 0.125 μM, 0.250 μM, 0.500 μM, 1 μM
-
Incubation Time:14 day
-
Result:Inhibited androgen-mediated colony formation efficiency in a concentration-dependent manner.
Reduced relative colony number to near baseline levels (comparable to cells treated with DMSO without R1881) at 1 μM.
-
Cell Line:AKR1C3-overexpressing LNCaP (LNCaP AKR1C3) prostate cancer cells, vector control LNCaP Puro cells
-
Concentration:0.1 μM, 1 μM, 10 μM
-
Incubation Time:14 day
-
Result:Resulted in significantly higher colony formation efficiency in LNCaP AKR1C3 cells than LNCaP Puro cells at all tested concentrations.
Achieved a relative colony number (normalized to DMSO) of ~0.45 for LNCaP AKR1C3 cells at 0.1 μM.
Achieved a relative colony number (normalized to DMSO) of ~0.4 for LNCaP AKR1C3 cells at 10 μM.
Parmacokinetics
In Vivo
JNJ-pan-AR (30 mg/kg; p.o.; daily; 10 days) potently inhibits testosterone propionate-stimulated androgen-sensitive organ growth in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SHO (male, castrated)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; daily
-
Result:Achieved a tumor growth inhibition (TGI) of 80.2%.
Achieved a TGI of 100.8% (complete tumor growth stasis).
Reached a plasma exposure of 748 ng/mL.
Chemical Information
-
CAS. Nr. 1332390-06-3
-
Molecular Weight 515.55
-
Formel C25H24F3N5O2S
-
SMILES
N#CC1=NC=C(N2C(C3(CCC3)N(C2=S)C4=CC=C(C=C4)OC5CCN(CC5)C)=O)C=C1C(F)(F)F
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Soft Agar Colony Formation Assay
Soft agar colony formation assay measures anchorage-independent growth, in which transformed or tumorigenic cells proliferate as colonies in a semisolid agar matrix while many non-transformed adherent cells fail to proliferate without attachment; classic studies showed that growth in semisolid medium correlates with tumorigenicity in nude mice, and later protocol papers describe the method as a stringent in vitro assay for malignant transformation. The readout is the number, size, morphology, or signal intensity of colonies formed within agar after incubation; published formats include manual colony counting after staining, 96-well or 384-well quantitative formats, DNA-binding dye detection, MTT/tetrazolium-based detection, digital image analysis, and PCR-based marker detection from soft agar cultures.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
Reinheit & Dokumentation
Verweise
[1]. Zhang Z, et al. Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). J Med Chem. 2021;64(2):909-924. [Content Brief]
[2]. Hertzog JR, et al. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer. Prostate. 2020;80(14):1223-1232. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)